Abstract: A DNA coding for a fusion protein comprising a polypeptide having the antigenicity of Mycoplasma gallisepticum and a polypeptide derived from Herpesvirus outer membrane protein, in which the polypeptide derived from the outer membrane protein has been ligated with the polypeptide having the antigenicity of Mycoplasma gallisepticum at the N terminus thereof, is prepared. The DNA is inserted into a region non-essential to growth of Avipox virus and the resulting recombinant Avipox virus is provided as a more potent recombinant virus as an anti-Mycoplasma vaccine.

Abstract: The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding, the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype 1 strains. The present invention further provides an avian recombinant herpesvirus comprised of the VP2 gene of which the backbone virus is a Marek's disease vaccine strain, such as herpesvirus of turkeys. A poultry vaccine including the avian herpes recombinant virus described in the present invention can induce in chickens protective immunity against a variety of different subtypes of IBDV.

Abstract: There is provided a DNA molecule derived from a prokaryotic cell in which at least one of the DNA regions encoding NXB (N is asparagine, X is any amino acid other than proline, and B is serine or threonine) has been modified so that no N-glycosylation occurs during the expression in a eukaryotic cell, and since the DNA molecule has been modified at the N-glycosylation site, it produces a non-N-glycosylated protein, which thereby exhibits a high immunogenicity when, for example, it is allowed to produce, in a eukaryotic cell, an antigen protein derived from a prokaryotic cell.

Abstract: The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding, the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype 1 strains. The present invention further provides an avian recombinant herpesvirus comprised of the VP2 gene of which the backbone virus is a Marek's disease vaccine strain, such as herpesvirus of turkeys. A poultry vaccine including the avian herpes recombinant virus described in the present invention can induce in chickens protective immunity against a variety of different subtypes of IBDV.

Abstract: There is provided a DNA molecule derived from a prokaryotic cell in which at least one of the DNA regions encoding NXB (N is asparagine, X is any amino acid other than proline, and B is serine or threonine) has been modified so that no N-glycosylation occurs during the expression in a eukaryotic cell, and since the DNA molecule has been modified at the N-glycosylation site, it produces a non-N-glycosylated protein, which thereby exhibits a high immunogenicity when, for example, it is allowed to produce, in a eukaryotic cell, an antigen protein derived from a prokaryotic cell.

Abstract: There is provided a DNA molecule derived from a prokaryotic cell in which at lest one of the DNA regions encoding NXB (N is asparagine, X is any amino acid other than proline, and b is serine or threonine) has been modified so that no N-glycosylation occurs buring the expression in a eukaryotic cell, and since the DNA molecule has been modified at the N-glycosylation site, it produces a non-N-glycosylated protein, which thereby exhibits a high immunogenicity when, for example, it is allowed to produce, in a eukaryotic cell, an antigen protein derived from a prokaryotic cell.

Abstract: The present invention discloses a DNA molecule that encodes a polypeptide that has the amino acid sequence described in SEQ ID No. 2 or an amino acid sequence that is at least 80% homologous with said amino acid sequence, a recombinant containing said DNA molecule, and a vaccine having for its active ingredient said recombinant.

Abstract: A DNA coding for a fusion protein comprising a polypeptide having the antigenicity of Mycoplasma gallisepticum and a polypeptide derived from Herpesvirus outer membrane protein, in which the polypeptide derived from the outer membrane protein has been ligated with the polypeptide having the antigenicity of Mycoplasma gallisepticum at the N terminus thereof, is prepared. The DNA is inserted into a region non-essential to growth of Avipox virus and the resulting recombinant Avipox virus is provided as a more potent recombinant virus as an anti-Mycoplasma vaccine.